These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23588735)

  • 1. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
    Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
    J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
    Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
    Front Immunol; 2018; 9():335. PubMed ID: 29563911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.
    Ersching J; Hernandez MI; Cezarotto FS; Ferreira JD; Martins AB; Switzer WM; Xiang Z; Ertl HC; Zanetti CR; Pinto AR
    Virology; 2010 Nov; 407(1):1-6. PubMed ID: 20797754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.
    Chen H; Xiang ZQ; Li Y; Kurupati RK; Jia B; Bian A; Zhou DM; Hutnick N; Yuan S; Gray C; Serwanga J; Auma B; Kaleebu P; Zhou X; Betts MR; Ertl HC
    J Virol; 2010 Oct; 84(20):10522-32. PubMed ID: 20686035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.
    Yu B; Zhou Y; Wu H; Wang Z; Zhan Y; Feng X; Geng R; Wu Y; Kong W; Yu X
    J Med Virol; 2012 Sep; 84(9):1408-14. PubMed ID: 22825819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
    Mast TC; Kierstead L; Gupta SB; Nikas AA; Kallas EG; Novitsky V; Mbewe B; Pitisuttithum P; Schechter M; Vardas E; Wolfe ND; Aste-Amezaga M; Casimiro DR; Coplan P; Straus WL; Shiver JW
    Vaccine; 2010 Jan; 28(4):950-7. PubMed ID: 19925902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
    Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
    Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China.
    Jian L; Zhao Q; Zhang S; Huang W; Xiong Y; Zhou X; Jia B
    Arch Virol; 2014 Mar; 159(3):465-70. PubMed ID: 24057756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China.
    Sun C; Zhang Y; Feng L; Pan W; Zhang M; Hong Z; Ma X; Chen X; Chen L
    Vaccine; 2011 May; 29(22):3837-41. PubMed ID: 21447314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
    Zheng X; Rong X; Feng Y; Sun X; Li L; Wang Q; Wang M; Liu W; Li C; Yang Y; Zhou R; Lu J; Feng L; Chen L
    Emerg Microbes Infect; 2017 Jun; 6(6):e43. PubMed ID: 28588291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
    Dicks MD; Spencer AJ; Edwards NJ; Wadell G; Bojang K; Gilbert SC; Hill AV; Cottingham MG
    PLoS One; 2012; 7(7):e40385. PubMed ID: 22808149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of Human Adenovirus Type 5 Neutralizing Antibody in Common Marmosets Determined by a New Set of Two Assays.
    Wang Q; Sun Y; Xu Y; Wang Y; Wang H; Fu Y; Allain JP; Li C; Li T
    Viral Immunol; 2019 Oct; 32(8):348-354. PubMed ID: 31433272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
    Fitzgerald JC; Gao GP; Reyes-Sandoval A; Pavlakis GN; Xiang ZQ; Wlazlo AP; Giles-Davis W; Wilson JM; Ertl HC
    J Immunol; 2003 Feb; 170(3):1416-22. PubMed ID: 12538702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
    Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
    Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.
    Appaiahgari MB; Pandey RM; Vrati S
    Clin Vaccine Immunol; 2007 Aug; 14(8):1053-5. PubMed ID: 17596429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
    Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
    Pilankatta R; Chawla T; Khanna N; Swaminathan S
    J Med Virol; 2010 Mar; 82(3):407-14. PubMed ID: 20087930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
    Nébié I; Edwards NJ; Tiono AB; Ewer KJ; Sanou GS; Soulama I; Sanon S; Diarra A; Yaro JB; Kangoye D; Imoukhuede EB; Hill AV; Sirima SB
    Clin Vaccine Immunol; 2014 Jun; 21(6):901-3. PubMed ID: 24739980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.
    Smaill F; Jeyanathan M; Smieja M; Medina MF; Thanthrige-Don N; Zganiacz A; Yin C; Heriazon A; Damjanovic D; Puri L; Hamid J; Xie F; Foley R; Bramson J; Gauldie J; Xing Z
    Sci Transl Med; 2013 Oct; 5(205):205ra134. PubMed ID: 24089406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis.
    Wang C; Dulal P; Zhou X; Xiang Z; Goharriz H; Banyard A; Green N; Brunner L; Ventura R; Collin N; Draper SJ; Hill AVS; Ashfield R; Fooks AR; Ertl HC; Douglas AD
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006870. PubMed ID: 30372438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.